Annals of Oncology March 2024 issue article of the month
Annals of Oncology shared a post by Annals of Oncology on X/Twitter, adding:
”The article by Giorgio Bogani and collaborators on immunotherapy in advanced endometrial cancer is the Annals of Oncology March 2024 issue article of the month.
A tutorial:
Results of a meta-analysis of the 4 RCTs evaluating immunotherapy and chemotherapy in first line endometrial cancer. Platinum-based chemotherapy was the standard of care since the results of the GOG209 trial. Immunotherapy transformed the current landscape.
In 2023, the preliminary results of studies testing anti-PD-1/PD-L1 in combination with 1st line chemotherapy were released. In all comers, chemotherapy plus immunotherapy followed by immunotherapy prolong response rate in advanced /metastatic endometrial cancers.
PD(L)1 drugs improve outcomes regardless of MMR status . Immunotherapy and chemotherapy combinations showed activity in endometrial cancer, particularly in MMRd disease.
Even in the MMR preserved population, immunotherapy correlates with improved outcomes (to a lesser extent). Adding immunotherapy provides a clinically meaningful trend in reduced risk of death by about 20%.
Addition of PARPi (olaparib) to anti-PDL-1 (durvalumab) enhanced PFS benefit in the MMRp/MSS and the PD-L1–positive subgroups, regardless of HRR status.
Non-responsive patients necessitate more precise and effective treatment modalities Ongoing trials are testing trastuzumab deruxtecan (T-DXd), selinexor, WEE1 inhibitors and CDK4/6 inhibitors.
Giorgio Bogani sets the stage and explains what to expect in this video from the video highlights series.”
Quoting Annals of Oncology’s post:
”Just out in Annals of Oncology, a review and meta-analysis by Giorgio Bogani and collaborators of phase III trials investigating the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer. Read further.
They assess:
- The role of frontline immuno-oncology.
- The role of combination of chemo and immunotherapy in MMRd endometrial cancer.
- The role of combination of chemo and immunotherapy in MMRp endometrial cancers.
- Molecular-based therapy.
- Biomarker-driven therapy.”
Source: Annals of Oncology/X and Annals of Oncology/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023